Pharmalotby Ed SilvermanOctober 22, 2015
Thanks to a compounding pharmacy, Martin Shkreli’s company may no longer have a lock on the market for its pricey anti-infective drug Daraprim. A little-known company called Imprimis Pharmaceuticals announced plans to make a combination medicine that includes pyrimethamine, the same active ingredient found in Daraprim. And Imprimis intends to charge just $99 for a bottle of 100 capsules, or about $1 each. Daraprim costs $750 per tablet.
Shkreli’s Turing Pharmaceuticals, as you know, caused a recent firestorm by boosting the price of Daraprim from $13.55 less than a month after buying the decades-old, life-saving medicine from another drug maker this summer. The price hike amounted to a whopping 5,433 percent increase.
Turing sparked still more outrage by restricting distribution in order to thwart generic drug makers from obtaining samples needed to develop cheaper versions. This prompted the New York Attorney General to launch an anti-trust probe last week. And US Senator Amy Klobuchar, a Minnesota Democrat and Presidential hopeful Hillary Clinton asked the Federal Trade Commission to do the same.“We’re going to take care of this patient population and at a fair price and make a great profit,” Imprimis chief executive officer Mark Baum told us. “We think physicians will write prescriptions for the compounded version. And we think insurers will support this”…